Subjective morbidity and quality of life after sentinel node biopsy and axillary lymph node dissection for breast cancer
Article first published online: 22 SEP 2005
Copyright © 2005 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 92, Issue 1, pages 17–22, 1 October 2005
How to Cite
Barranger, E., Dubernard, G., Fleurence, J., Antoine, M., Darai, E. and Uzan, S. (2005), Subjective morbidity and quality of life after sentinel node biopsy and axillary lymph node dissection for breast cancer. J. Surg. Oncol., 92: 17–22. doi: 10.1002/jso.20343
- Issue published online: 22 SEP 2005
- Article first published online: 22 SEP 2005
- Manuscript Accepted: 16 MAR 2005
- Manuscript Received: 18 MAY 2004
- breast cancer;
- sentinel lymph node;
Background and Objectives
Sentinel node (SN) biopsy is a minimally invasive surgical method for axillary staging in patients with breast cancer. The aim of this study was to evaluate mid-term morbidity after SN biopsy and axillary lymph node (ALN) dissection in patients with breast cancer receiving breast-sparing treatment, and to determine its impact on quality of life (QOL).
One hundred fifteen patients with breast cancer underwent breast-conserving treatment with SN biopsy alone (Group 1: n = 54), ALN dissection with or without SN biopsy (Group 2: n = 51), or SN biopsy followed by later ALN dissection (Group 3: n = 10).
The mean post-operative follow-up was 20.3 months (range: 10–31 months) in Group 1, 24.3 months (range: 10–33 months) in Group 2, and 19.1 months (range: 12–28 months) in Group 3. Arm-shoulder pain was reported by 21.2% of patients in Group 1, 52.9% in Group 2, and 60% in Group 3 (P = 0.002). An arm swelling sensation was reported by 0% of patients in Group 1, 21.6% in Group 2, and 10% in Group 3. Dysesthesias were reported by 5.7% of patients in Group 1, 51% in Group 2, and 50% in Group 3 (P < 0.001). The mean global QOL self-rating score was 7.6 in Group 1, 7.6 in Group 2, and 7.7 in Group 3 (no significant difference).
SN biopsy is associated with significantly lower mid-term morbidity than ALN dissection. J. Surg. Oncol. 2005;92:17–22. © 2005 Wiley-Liss, Inc.